NHGRI Launches Natural History Study of 600 Patients for Hermansky-Pudlak Syndrome, Aiming to Develop Targeted Therapies
Rare Genetic Disease HPS: Molecular Characteristics and Mortality
Hermansky-Pudlak syndrome (HPS) is a rare genetic disorder characterized by oculocutaneous albinism and a bleeding tendency due to platelet storage pool deficiency. It is marked by the accumulation of abnormal lipid-protein complexes, called ceroid lipofuscin, within lysosomes. Pulmonary fibrosis (PF), a life-threatening complication in patients, reduces life expectancy to 40-50 years. Currently, there are no approved treatments, resulting in a significant unmet medical need, with existing therapies only providing symptomatic relief.
Strategic Intent of the NHGRI Natural History Study
The National Human Genome Research Institute (NHGRI) is conducting a natural history study (NCT00001456) involving 600 patients. The study aims to perform long-term follow-up on a patient cohort ranging from 1 to 80 years of age, collecting genetic variation data and patient biospecimens. Although the global prevalence of this rare disease is 1-9 per million, it exhibits complexity with 11 subtypes (HPS-1 to 11) based on genetic variations. This database will play a crucial role in the long term by establishing key targets for the development of new, personalized, targeted gene therapies.
Past Clinical Trial Failures and Development Challenges
Previous clinical trials using pirfenidone to treat HPS-associated pulmonary fibrosis (NCT00021596) were discontinued due to a lack of demonstrated efficacy. Clinical trials using combination therapies with losartan, etc. (NCT00467831) also failed to show significant effectiveness. This is because HPS-associated pulmonary fibrosis follows a different lysosomal accumulation pathway compared to general pulmonary fibrosis. Consequently, the biopharma industry has recently focused on fundamental treatments through gene delivery or CRISPR/Cas9 gene editing.
HPS Market Growth and Venture Capital Investment Perspective
The HPS therapeutics market is projected to grow from $7.4 billion in 2026 to $14.82 billion in 2036, with an annual growth rate of 7.2%. The increasing availability of NGS diagnostics and FDA Orphan Drug Designation (ODD) benefits are stimulating pipeline research by global pharmaceutical companies. Currently, there are no approved exclusive drugs on the market, but as cohort data is accumulated, the success rate of new drug development will increase. From an investor's perspective, this clinical data can be used to validate the efficacy of early-stage pipelines and reduce risk.
Hermansky-Pudlak syndrome (HPS) is a rare disease with a global prevalence of 1-9 per million, but the global therapeutics market has the potential to grow from $7.4 billion in 2026 to $14.82 billion in 2036, with an annual growth rate of 7.2%. The NHGRI's natural history study (NCT00001456) involving 600 patients is a short-term catalyst for resolving bottlenecks in the drug discovery phase by establishing subtype (HPS-1 to 11)-specific fluid and genetic biomarkers. In the medium to long term, it will serve as a foundational clinical infrastructure that increases the likelihood of phase 1 entry for next-generation targets, such as lentiviral-based gene therapies and CRISPR/Cas9 gene editing pipelines, learning from the lessons of the failed pirfenidone (NCT00021596) clinical trial. Given the absence of competing treatment options, the first approved drug is highly likely to have market exclusivity, so venture capital and pharmaceutical companies should closely analyze the level of biospecimen database acquisition in this study to proactively hedge investment risks.
Source: ClinicalTrials.gov (api_ct)